| Autor: |
Buentzel J; Department of Hematology and Medical Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany., Klemp HG; Department of Pediatrics and Adolescent Medicine, University Medical Center Goettingen, 37075 Goettingen, Germany., Kraetzner R; Department of Pediatrics and Adolescent Medicine, University Medical Center Goettingen, 37075 Goettingen, Germany., Schulz M; Department of Hematology and Medical Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany., Dihazi GH; Metabolomics Platform, Department of Clinical Chemistry, University Medical Center Goettingen, 37075 Goettingen, Germany., Streit F; Metabolomics Platform, Department of Clinical Chemistry, University Medical Center Goettingen, 37075 Goettingen, Germany., Bleckmann A; Department of Hematology and Medical Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany.; Department of Medicine A (Hematology, Oncology, Hemostaseology and Pulmonology), University Hospital Muenster, 48149 Muenster, Germany., Menck K; Department of Medicine A (Hematology, Oncology, Hemostaseology and Pulmonology), University Hospital Muenster, 48149 Muenster, Germany., Wlochowitz D; Medical Bioinformatics, University Medical Center Goettingen, 37075 Goettingen, Germany., Binder C; Department of Hematology and Medical Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany. |
| Abstrakt: |
Malignant cells differ from benign ones in their metabolome and it is largely unknown whether this difference is reflected in the metabolic profile of their microvesicles (MV), which are secreted into the blood of cancer patients. Here, they are present together with MV from the various blood and endothelial cells. Harvesting MV from 78 breast cancer patients (BC) and 30 controls, we characterized the whole blood MV metabolome using targeted and untargeted mass spectrometry. Especially (lyso)-phosphatidylcholines and sphingomyelins were detected in a relevant abundance. Eight metabolites showed a significant discriminatory power between BC and controls. High concentrations of lysoPCaC26:0 and PCaaC38:5 were associated with shorter overall survival. Comparing BC subtype-specific metabolome profiles, 24 metabolites were differentially expressed between luminal A and luminal B. Pathway analysis revealed alterations in the glycerophospholipid metabolism for the whole cancer cohort and in the ether lipid metabolism for the molecular subtype luminal B. Although this mixture of blood-derived MV contains only a minor number of tumor MV, a combination of metabolites was identified that distinguished between BC and controls as well as between molecular subtypes, and was predictive for overall survival. This suggests that these metabolites represent promising biomarkers and, moreover, that they may be functionally relevant for tumor progression. |
